Revatio Portal-Pulmonary Arterial Hypertension Trial (RePo1 Trial): A Randomized, Double-blinded, Placebo-controlled, Multi-center Study to Evaluate the Effects of Sildenafil Citrate (Revatio) 20 mg TID on Patients With Portal Pulmonary Arterial Hypertension (PPAH)
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 12
- 试验地点
- 3
- 主要终点
- Change from baseline in PVR after 16 weeks of treatment
研究概览
简要总结
The investigators propose the first prospective, double blind, randomized controlled trial of treatment for pulmonary arterial hypertension (PAH) related to underlying portal hypertension. Specifically the investigators will evaluate the potential efficacy and safety of sildenafil (Revatio) in a 16 week blinded, multicentre study.
详细描述
PAH is a recognized complication of portal hypertension - termed portal-pulmonary hypertension (PPHTN). In the World Health Organization (WHO) classification PPHTN is categorized as a WHO group 1 condition. This categorization is appropriate as PPHTN shares similar pathological features and clinical presentation and as idiopathic (primary) pulmonary arterial hypertension (PAH). Advances in oral therapies in PAH (idiopathic, connective tissue disease, congenital heart disease) has deferred the need for parenteral therapies, lung transplantation and led to improvements in functional capacity, quality of life and survival. However unlike other forms of PAH, treatment options have not been formally evaluated for PPHTN and there are no approved medical therapies. Patients are unable to pay for medications. Consequently patients continue to endure the natural progression of PAH - a state characterized by progressive right heart failure, disability and death. Furthermore the unacceptable mortality associated with liver transplantation in the presence of hemodynamically significant PAH, leaves them with no therapeutic options. Therefore, new treatment options need to be systematically evaluated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female patients with PPHTN.
- •A 6MWD test between 150 m and 450 m.
- •A pulmonary vascular resistance (PVR) >250 dyn*sec*cm-5, a mean pulmonary artery pressure (PAPmean) ≥25 mmHg due to portal hypertension, and PCWP ≤ 15 mmHg. Right-heart catheterization results for the definite diagnosis of PH must follow the 2 - 6 week pre-treatment phase and not be older than 6 weeks at study start (will be considered as baseline values).
- •Portal hypertension defined either clinically or hemodynamically by the presence of cirrhosis (by ultrasound or biopsy) or portal vein thrombosis / obstruction (proven by portal vein Doppler) and any one of the following within one year of entry into the study: 1) Ascites (on ultrasound of the abdomen); 2) Splenomegaly (on ultrasound of the abdomen); 3) Esophageal or Gastric Varices (proven endoscopically); 4) Hepatic-venous pressure gradient (HVPG) > 12 mmHg.
- •Treatment naive patients (with respect to PAH specific medication) and patients. Prior use of sildenafil for erectile dysfunction will be permitted.
- •18 to 75 years of age at Visit
- •Patients who are able to understand and follow instructions and who are able to participate in the study for the entire period.
- •Patients must have given their written informed consent to participate in the study after having received adequate previous information and prior to any study-specific procedures.
排除标准
- •Participation in another clinical trial during the preceding 3 months.
- •Pregnant women or breast feeding women.
- •Patients with a medical disorder, condition, or history of such that would impair the patient's ability to participate or complete this study in the opinion of the investigator or the sponsor.
- •Patients with a history of severe allergies or multiple drug allergies.
- •Patients with hypersensitivity to the investigational drug or inactive constituents.
研究组 & 干预措施
Revatio
干预措施: Sildenafil (Drug)
Placebo
干预措施: Placebo (Drug)
结局指标
主要结局
Change from baseline in PVR after 16 weeks of treatment
时间窗: 16 weeks
次要结局
- Change from baseline in CAMPHOR and SF-36 measures of quality of life(16 weeks)
- Complications of liver disease(16 weeks)
- Renal dysfunction(16 weeks)
- Desaturation(16 weeks)
- Change in 6MWD from baseline(16 weeks)
- Change in Brain Natruretic Peptide (BNP) from baseline(16 weeks)
- Death(16 weeks)
- MELD score(16 weeks)
- Change in baseline WHO functional class(16 weeks)
- For patients with a PVR>450 dynes/sec/cm5 at baseline, number of patients who have PVR below 350 dynes/sec/cm5 after 16 weeks of study drug will be determined(16 weeks)
- Hospitalizations(16 weeks)